title: Management of hidradenitis suppurativa with biological therapy: report of four cases and review of the literature.
abstract: Several studies report the usefulness of different biological therapies in the management of a difficult-to-treat pathology such as hidradenitis suppurativa (HS). However, there are little data on this, which shows the great difficulty in the management of this disease. We will report herein our experience of the treatment of four complex cases of HS. We will also review previous cases published in the literature in order to further assess the results obtained with different biological drugs in terms of efficacy and safety. We conclude that, in the near future, biological therapy could become an essential tool in the management of cases of HS who have not previously responded to classical treatment.
authors.affiliation: Department of Dermatology, Hospital Virgen del Valle, Toledo, Spain.
authors.forename: Constanza
authors.initials: C
authors.lastname: Bahillo Monné
authors.forename: Silvia
authors.initials: S
authors.lastname: Honorato Guerra
authors.forename: Cristina
authors.initials: C
authors.lastname: Schoendorff Ortega
authors.forename: Ana Belen
authors.initials: AB
authors.lastname: Gargallo Quintero
mesh_terms: D000068879:Adalimumab; D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000627:therapeutic use*; D001691:Biological Therapy; D003879:Dermatologic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000068800:Etanercept; D005260:Female; D017497:Hidradenitis Suppurativa / Q000188:drug therapy* / Q000601:surgery; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use; D000069285:Infliximab; D008297:Male; D008875:Middle Aged; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use; D019233:Retreatment; D017211:Treatment Failure; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*; D055815:Young Adult
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D003879:Dermatologic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000068879:Adalimumab; D000068800:Etanercept